Ana Flávia Marques Pereira

Dr. Ana Flávia Marques Pereira

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Microbial Pathogenesis
Verified
Journal Article
Closed access
MAMariana Albano
Mariana Albano
BCBruno Pereira Crulhas
Bruno Pereira Crulhas
FAFernanda Cristina Bérgamo Alves
Fernanda Cristina Bérgamo Alves
Ana Flávia Marques PereiraAna Flávia Marques Pereira
Ana Flávia Marques Pereira
BABruna Fernanda Murbach Teles Andrade
Bruna Fernanda Murbach Teles Andrade
AJAry Fernandes Júnior
Ary Fernandes Júnior

1 April 2020 in Microbial Pathogenesis
Verified
Journal Article
Closed access
Ana Flávia Marques PereiraAna Flávia Marques Pereira
Ana Flávia Marques Pereira
MAMariana Albano
Mariana Albano
FAFernanda Cristina Bérgamo Alves
Fernanda Cristina Bérgamo Alves
BABruna Fernanda Murbach Teles Andrade
Bruna Fernanda Murbach Teles Andrade
AFAlessandra Furlanetto
Alessandra Furlanetto
AJAry Fernandes Júnior
Ary Fernandes Júnior

1 December 2016 in Innovative Food Science & Emerging Technologies
Verified
Journal Article
Closed access
MAMariana Albano
Mariana Albano
FAFernanda Cristina Bérgamo Alves
Fernanda Cristina Bérgamo Alves
BABruna Fernanda Murbach Teles Andrade
Bruna Fernanda Murbach Teles Andrade
LBLidiane Nunes Barbosa
Lidiane Nunes Barbosa
Ana Flávia Marques PereiraAna Flávia Marques Pereira
Ana Flávia Marques Pereira
AJAry Fernandes Júnior
Ary Fernandes Júnior

13 December 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Ana Flávia Marques PereiraAna Flávia Marques Pereira
Ana Flávia Marques Pereira
JCJoeliton S. Cavalcante
Joeliton S. Cavalcante
DADAVI GOMES ANGSTMAM
DAVI GOMES ANGSTMAM
CACayo Antônio Soares de Almeida
Cayo Antônio Soares de Almeida
GSGean Souza Soares
Gean Souza Soares
Rui Seabra Ferreira JuniorRui Seabra Ferreira Junior
Rui Seabra Ferreira Junior
The concept of pain encompasses a complex interplay of sensory and emotional experiences associated with actual or potential tissue damage. Accurately describing and localizing pain, whether acute or chronic, mild or severe, poses a challenge due to its diverse manifestations. Understanding the underlying origins and mechanisms of these pain variations is crucial for effective management and pharmacological interventions. Derived from a wide spectrum of species, including snakes, arthropods, mollusks, and vertebrates, animal venoms have emerged as abundant repositories of potential biomolecules exhibiting analgesic properties across a broad spectrum of pain models. This review focuses on highlighting the most promising venom-derived toxins investigated as potential prototypes for analgesic drugs. The discussion further encompasses research prospects, challenges in advancing analgesics, and the practical application of venom-derived toxins. As the field continues its evolution, tapping into the latent potential of these natural bioactive compounds holds the key to pioneering approaches in pain management and treatment. Therefore, animal toxins present countless possibilities for treating pain caused by different diseases. The development of new analgesic drugs from toxins is one of the directions that therapy must follow, and it seems to be moving forward by recommending the composition of multimodal therapy to combat pain.

27 November 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
Ana Flávia Marques PereiraAna Flávia Marques Pereira
Ana Flávia Marques Pereira
ASAlessandra Aguirra Sani
Alessandra Aguirra Sani
TZTatiane Baptista Zapata
Tatiane Baptista Zapata
DSDébora Silva Marques de Sousa
Débora Silva Marques de Sousa
BRBruno C. Rossini
Bruno C. Rossini
AJAry Fernandes Junior
Ary Fernandes Junior
Methicillin-resistant Staphylococcus aureus (MRSA) often cause infections with high mortality rates. Antimicrobial peptides are a source of molecules for developing antimicrobials; one such peptide is melittin, a fraction from the venom of the Apis mellifera bee. This study aimed to evaluate the antibacterial and antibiofilm activities of melittin and its association with oxacillin (mel+oxa) against MRSA isolates, and to investigate the mechanisms of action of the treatments on MRSA. Minimum inhibitory concentrations (MICs) were determined, and synergistic effects of melittin with oxacillin and cephalothin were assessed. Antibiofilm and cytotoxic activities, as well as their impact on the cell membrane, were evaluated for melittin, oxacillin, and mel+oxa. Proteomics evaluated the effects of the treatments on MRSA. Melittin mean MICs for MRSA was 4.7 μg/mL and 12 μg/mL for oxacillin. Mel+oxa exhibited synergistic effects, reducing biofilm formation, and causing leakage of proteins, nucleic acids, potassium, and phosphate ions, indicating action on cell membrane. Melittin and mel+oxa, at MIC values, did not induce hemolysis and apoptosis in HaCaT cells. The treatments resulted in differential expression of proteins associated with protein synthesis and energy metabolism. Mel+oxa demonstrated antibacterial activity against MRSA, suggesting a potential as a candidate for the development of new antibacterial agents against MRSA.

1 January 2022 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
ASAlessandra Aguirra Sani
Alessandra Aguirra Sani
Ana Flávia Marques PereiraAna Flávia Marques Pereira
Ana Flávia Marques Pereira
AFAlessandra Furlanetto
Alessandra Furlanetto
DSDébora Silva Marques de Sousa
Débora Silva Marques de Sousa
TZTatiane Baptista Zapata
Tatiane Baptista Zapata
AJAry Fernandes Junior
Ary Fernandes Junior
Natural products represent important sources of antimicrobial compounds. Propolis and compounds from essential oils comprise good examples of such substances because of their inhibitory effects on bacterial spores, including bee pathogens. Ethanol extracts of propolis (EEP) from Apis mellifera were prepared using different methods: double ultrasonication, double maceration and maceration associated with ultrasonication. Together with the antimicrobial peptides nisin and melittin, and compounds present in the essential oils of clove (Syzygium aromaticum) and cinnamon (Cinnamomum zeylanicum), assays were carried out on one Bacillus subtilis isolate and Paenibacillus alvei (ATCC 6344) against vegetative and sporulated forms, using the resazurin microtiter assay. Synergism with all the antimicrobials in association with tetracycline was verified by the time-kill curve method. Potassium and phosphate efflux, release of proteins and nucleic acids were investigated. EEPs showed the same MIC, 156.25 µg/mL against B. subtilis and 78.12 µg/mL against P. alvei. The peptides showed better activities against B. subtilis (MIC of 12 µg/mL for melittin and 37.50 µg/mL for nisin). Antimicrobials showed similar inhibitory effects, but cinnamaldehyde (39.06 µg/mL) showed the best action against P. alvei. Melittin and nisin showed the greatest capacity to reduce spores, regarding B. subtilis there was a 100% reduction at 6.25 and 0.78 µg/mL, respectively. Concerning P. alvei, the reduction was 93 and 98% at concentrations of 80 µg/mL of melittin and 15 µg/mL of nisin. EEPs showed the highest effects on the protein release against B. subtilis and P. alvei. Nucleic acid release, phosphate and potassium efflux assays indicated bacterial cell membrane damage. Synergism between antimicrobials and tetracycline was demonstrated against both bacteria. All antimicrobials tested showed antibacterial activities against vegetative and sporulated forms of P. alvei and B. subtilis, especially nisin and melittin. Synergism with tetracycline and damage on bacterial cell membrane also occurred.